ENDRA Life Sciences Depreciation & Amortization Growth & History (NDRA)
ENDRA Life Sciences's depreciation and amortization was $44,045 for fiscal 2025.
View full ENDRA Life Sciences company overviewENDRA Life Sciences annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44,045 | −$2,444 | −5.26% |
| 2024 | 2024-12-31 | $46,489 | −$77,237 | −62.43% |
| 2023 | 2023-12-31 | $123,726 | $27,065 | +28.00% |
| 2022 | 2022-12-31 | $96,661 | −$19,577 | −16.84% |
| 2021 | 2021-12-31 | $116,238 | $16,896 | +17.01% |
| 2020 | 2020-12-31 | $99,342 | $18,765 | +23.29% |
| 2019 | 2019-12-31 | $80,577 | $12,261 | +17.95% |
| 2018 | 2018-12-31 | $68,316 | $6,835 | +11.12% |
| 2017 | 2017-12-31 | $61,481 | −$3,455 | −5.32% |
| 2016 | 2016-12-31 | $64,936 | — | — |
ENDRA Life Sciences quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8,156 | −$1,200 | −12.83% |
| Q1 2026 | 2026-03-31 | $9,492 | −$4,294 | −31.15% |
| Q4 2025 | 2025-12-31 | $39,532 | — | — |
| Q3 2025 | 2025-09-30 | $10,786 | −$710 | −6.18% |
| Q2 2025 | 2025-06-30 | $9,356 | $663 | +7.63% |
| Q1 2025 | 2025-03-31 | $13,786 | −$1,514 | −9.90% |
| Q3 2024 | 2024-09-30 | $11,496 | −$20,562 | −64.14% |
| Q2 2024 | 2024-06-30 | $8,693 | −$26,572 | −75.35% |
| Q1 2024 | 2024-03-31 | $15,300 | −$19,216 | −55.67% |
| Q3 2023 | 2023-09-30 | $32,058 | $8,265 | +34.74% |
| Q2 2023 | 2023-06-30 | $35,265 | $13,564 | +62.50% |
| Q1 2023 | 2023-03-31 | $34,516 | $15,478 | +81.30% |
| Q3 2022 | 2022-09-30 | $23,793 | −$6,030 | −20.22% |
| Q2 2022 | 2022-06-30 | $21,701 | −$12,028 | −35.66% |
| Q1 2022 | 2022-03-31 | $19,038 | −$12,387 | −39.42% |
| Q3 2021 | 2021-09-30 | $29,823 | $28,723 | +2611.18% |
| Q2 2021 | 2021-06-30 | $33,729 | $11,301 | +50.39% |
| Q1 2021 | 2021-03-31 | $31,425 | $9,839 | +45.58% |
| Q3 2020 | 2020-09-30 | $1,100 | −$18,829 | −94.48% |
| Q2 2020 | 2020-06-30 | $22,428 | $2,316 | +11.52% |
| Q1 2020 | 2020-03-31 | $21,586 | $1,954 | +9.95% |
| Q3 2019 | 2019-09-30 | $19,929 | $1,887 | +10.46% |
| Q2 2019 | 2019-06-30 | $20,112 | $5,247 | +35.30% |
| Q1 2019 | 2019-03-31 | $19,632 | $4,293 | +27.99% |
| Q3 2018 | 2018-09-30 | $18,042 | $2,885 | +19.03% |
| Q2 2018 | 2018-06-30 | $14,865 | −$409 | −2.68% |
| Q1 2018 | 2018-03-31 | $15,339 | −$351 | −2.24% |
| Q3 2017 | 2017-09-30 | $15,157 | −$1,183 | −7.24% |
| Q2 2017 | 2017-06-30 | $15,274 | −$817 | −5.08% |
| Q1 2017 | 2017-03-31 | $15,690 | −$491 | −3.03% |
| Q3 2016 | 2016-09-30 | $16,340 | — | — |
| Q2 2016 | 2016-06-30 | $16,091 | — | — |
| Q1 2016 | 2016-03-31 | $16,181 | — | — |
ENDRA Life Sciences depreciation and amortization trends
Over the last five fiscal years, ENDRA Life Sciences's depreciation and amortization decreased from $99,342 to $44,045, a change of −$55,297. The latest reported quarter, Q2 2026, shows $8,156.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ENDRA Life Sciences source filings ↗